Loading...
Ocrelizumab B cell depletion has no effect on HERV RNA expression in PBMC in MS patients
Tanasescu, Radu Gran, Bruno
Tanasescu, Radu
Gran, Bruno
Abstract
Background: Epstein barr virus (EBV) infection of B cells is now understood to be one of the triggering events for the development of Multiple Sclerosis (MS), a progressive immune-mediated disease of the central nervous system. EBV infection is also linked to expression of human endogenous retroviruses (HERVs) of the HERV-W group, a further risk factor for the development of MS. Ocrelizumab is a high-potency disease-modifying treatment (DMT) for MS, which depletes B cells by targeting CD20. Objective(s): We studied the effects of ocrelizumab on gene expression in peripheral blood mononuclear cells (PBMC) from paired samples from 20 patients taken prior to and 6 months after beginning ocrelizumab therapy. We hypothesised that EBV and HERV-W loads would be lower in post-treatment samples. Method(s): Samples were collected in Paxgene tubes, subject to RNA extraction and Illumina paired end short read mRNA sequencing with mapping of sequence reads to the human genome using Salmon and differential gene expression compared with DeSeq2. Mapping was also performed separately to the HERV-D database of HERV sequences and the EBV reference sequence. Result(s): Patient samples were more strongly clustered by individual rather than disease type (relapsing/remitting or primary progressive), treatment (pre and post), age, or sex. Fourteen genes, all clearly linked to B cell function were significantly down regulated in the post treatment samples. Interestingly only one pre-treatment sample had detectable EBV RNA and there were no significant differences in HERV expression (of any group) between pre- and post-treatment samples. Conclusion(s): While EBV and HERV expression are clearly linked to triggering MS pathogenesis, it does not appear that high level expression of these viruses is a part of the ongoing disease process or that changes in virus load are associated with ocrelizumab treatment.Copyright © 2024
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2024
Type
Article
Collections
Citation
Tarlinton, R., Tanasescu, R., Shannon-Lowe, C. and Gran, B. (2024) 'Ocrelizumab B cell depletion has no effect on HERV RNA expression in PBMC in MS patients', Multiple Sclerosis and Related Disorders, 86, 105597. doi: 10.1016/j.msard.2024.105597 https://doi.org/10.1016/j.msard.2024.105597.